Moderna shares dropped sharply on October 22, wiping roughly $24 billion off the company's market value, even though the Phase III INTerpath-001 trial showed its personalised melanoma vaccine cut the risk of recurrence or death by 42% versus Keytruda alone. The decline followed a rally of more than 500% this year that had already baked in a high degree of optimism.
The numbers behind the headline
The study enrolled more than 1,100 patients with high-risk melanoma and paired the experimental vaccine intismeran autogene with Merck's Keytruda. At two years, 82.2% of patients on the combination remained free of recurrence, compared with 70% on Keytruda monotherapy. The risk of distant metastasis or death fell 38%. Overall survival data are not yet mature.
Why the market shrugged
Investors treated the detailed readout as a sell-the-news event. The stock's ascent this year had priced in a best-case scenario, and the results, while clinically meaningful, did not exceed the elevated bar. Analysts also flagged open questions about commercial viability beyond melanoma and how the data compare with expectations set by earlier, smaller studies.
Technicals and the regulatory path
Shares slipped below key short-term moving averages, with the $176-$180 zone now watched as support and $160 cited as a potential downside target if that level breaks. On the regulatory front, Moderna and Merck are engaging with US authorities and targeting a 2027 launch. The longer-term opportunity hinges on survival follow-up and ongoing trials in lung, kidney and bladder cancer.